

Wisconsin Medicaid Pharmacy

Program & Policy

Overview

- Coverage
- Pricing
 - AWP
 - MAC List
- PA/PDL
 - Diagnosis Restriction
 - Prior Authorizaion
 - Rebates
- Physician Administered Drugs
- Pharmaceutical Care
- DERP
- CNS
- DUR
 - Retrospective
 - Prospective
 - Educational Interventions

Coverage

- Drug is FDA approved.
- The manufacturer signed a rebate agreement with the Centers for Medicare and Medicaid (CMS) and reported RPU information.
- The manufacturer has reported the NDC data and prices to First DataBank

Allowed Restrictions

- Prior Authorization
- Diagnosis Restriction
- Age/Sex Restriction
- Quantity Limits
- Drugs excluded from coverage
 - Less-than-effective as defined by the FDA.
 - Experimental or have no medically accepted indications

Pricing and Payment

- We reimburse the lesser of:
 - AWP-13%
 - MAC List
 - Usual and customary amount as billed by the pharmacy to private pay clients.

Prior Authorization and the Preferred Drug List

- Diagnosis Restriction
- Prior Authorization
 - Non-preferred Drugs
 - Brand Medically Necessary Drugs
- Drug Rebates
 - Federal
 - Supplemental
 - Provider Synergies
 - Multi-state

Physician Administered Drugs

- Reimburses ASP + 6%
- Billing – Professional vs Drug Claim Form
- Diagnosis Restrictions
- Rebates
- DRA 2005 will require all PAD claims to include NDC information

Pharmaceutical Care

- Reimburses pharmacists for additional actions they take beyond the standard dispensing and counseling for a prescription drug.
- Enhanced Dispensing Fee
- Commonly Billed Codes
 - Therapeutic Substitution
 - Insufficient Quantity
 - Suboptimal Regimen

Drug Effectiveness Review Project

- DERP is a collaboration of organizations that have joined together to obtain the best available evidence on effectiveness and safety comparisons between drugs in the same class, and to apply the information to public policy and decision making in local settings.
- 13 Medicaid programs & 1 Canadian organization.
- Member since 2003

Comprehensive NeuroScience

- Purpose - Improve the quality of behavioral health prescribing practice to optimize cost effectiveness.
- Monthly letters for specific criteria
 - 3 or more atypical antipsychotics
 - Multiple prescribers for any behavioral class
- Ended November 2006

Drug Utilization Review

- Retrospective
 - CNS Criteria
- Prospective
 - Suboptimal Regimen - For dose consolidation or tablet splitting
- Educational Interventions
 - Atypical Antipsychotic Intervention